Veru Inc VERU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERU is a good fit for your portfolio.
News
-
Veru Announces Date of 2024 Annual Meeting of Shareholders
-
Veru Reschedules Annual Meeting of Shareholders
-
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
-
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
-
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
-
Veru Reports Fiscal 2024 First Quarter Financial Highlights
-
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
-
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $1.28
- Day Range
- $1.28–1.38
- 52-Week Range
- $0.36–1.92
- Bid/Ask
- $1.32 / $1.34
- Market Cap
- $193.22 Mil
- Volume/Avg
- 1.6 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.46
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 233
- Website
- https://www.verupharma.com
Comparables
Valuation
|
Metric
|
VERU
|
ICVX
|
HLVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.74 | 3.30 | 2.26 |
Price/Sales | 7.46 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VERU
ICVX
HLVX
Financial Strength
|
Metric
|
VERU
|
ICVX
|
HLVX
|
|---|---|---|---|
Quick Ratio | 2.58 | 17.59 | 10.37 |
Current Ratio | 3.21 | 18.06 | 10.62 |
Interest Coverage | −36.30 | — | −54.72 |
Quick Ratio
VERU
ICVX
HLVX
Profitability
|
Metric
|
VERU
|
ICVX
|
HLVX
|
|---|---|---|---|
Return on Assets (Normalized) | −74.51% | −29.30% | −34.03% |
Return on Equity (Normalized) | −165.04% | −31.87% | −42.52% |
Return on Invested Capital (Normalized) | −110.86% | −34.69% | −38.62% |
Return on Assets
VERU
ICVX
HLVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fgzkwjbsb | Fwd | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jyfknlcf | Ffpqq | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cdcjhnzx | Hbrfg | $99.5 Bil | |
MRNA
| Moderna Inc | Zlmvjytd | Tdx | $38.8 Bil | |
ARGX
| argenx SE ADR | Vtxnxtc | Yfx | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Dlqbvwmg | Lyj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wnpfjld | Jdvsq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jqyzhnpv | Ykrhtdf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sytgwpxbg | Bnmtfv | $12.5 Bil | |
INCY
| Incyte Corp | Nqxcsxjx | Crfxsyb | $11.6 Bil |